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I. The Wonders of Modern Medicine and the Rise of the
Pharmaceutical Industry
Medical advances have altered the landscape of society in western
nations. Today, some diseases that were fatal just 70 years ago are now
either easily curable or completely eradicated.1 Other illnesses that were
considered incurable just 25 years ago, like AIDS, are now treatable, chronic
conditions.2 The Western world no longer fears contracting once deadly
diseases like smallpox or measles.3 Fortunately, many of the dangerous diseases
of our ancestors are curable with prescription medicine or other forms of
advanced treatment. In fact the population of individuals over the age of 85 is
expected to increase by roughly 350% between 2010 and 2050.4
Although it is remarkable to consider how far medicine has come, it is
equally as exciting to consider where medicine is headed. Some medical
professionals think that the children of Generation Z will regularly live to be
about 100 years old thanks in large part to the exponential advancement of

1. See Kevin Berman, Smallpox, MEDLINEPLUS, https://medlineplus.gov/ency/article/00
1356.htm (last updated Apr. 14, 2015), (noting smallpox is essentially eradicated today); see also
Erin Brodin, Seven Human Diseases the World is on the Cusp of Eradicating, BUSINESS INSIDER
(May 14, 2015, 11:48 AM), http://www.businessinsider.com/diseases-that-are-almost-eradicated2015-5/#measles-1 (listing seven diseases that are close to eradication thanks to modern medicine).
Specifically, the author notes that measles, rubella, polio, guinea worm, lymphatic filariasis,
onchocerciasis, and mumps as diseases that are close to being wiped out by medicine.
2. See Living with HIV, CTR. FOR DISEASE CONTROL & PREVENTION, http://www.cdc.gov/
actagainstaids/basics/livingwhiv.html (last updated Aug. 24, 2016) (discussing tips and
responsibilities associated with living with HIV); see also A Timeline of HIV/AIDS, AIDS.GOV,
https://www.aids.gov/hiv-aids-basics/hiv-aids-101/aids-timeline/ (last visited Mar. 26, 2017).
3. See Smallpox, COMMUNICABLE DISEASE CONTROL & PREVENTION, http://www.sfcdcp.org/
smallpox.html (last visited Mar. 26, 2017). Specifically, it is noted that the last case of smallpox in the
U.S. was in 1949, and the last case of smallpox in the world was in 1977 in Somalia.
4. See Laura F. Friedman, ‘One of Societies Greatest Achievements’ – In a Simple Chart of
The Past 175 Years, BUSINESS INSIDER (June 19, 2015, 4:40 PM), http://www.businessinsider.
com/how-has-life-expectancy-changed-throughout-history-2015-6 (citing the management of
infectious diseases as a main cause for increased life expectancy).
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medicine.5 In 2016, a man was successfully given two new arms that are
expected to become functional.6 Frequently it is reported that a cure for
cancer is imminent and life expectancies are increasing for almost all forms
of cancer.7 There is evidence to suggest that a vaccine to treat Ebola is closer
than most people might expect.8
Notwithstanding incredible progress, medical advancements continue
and it is clear more can be done to ease suffering and prolong life.
Developing, testing and researching new treatments for patient use in the
United States is an arduous process, and it is both expensive and time
consuming.9 Every prescription drug that is available to the masses has to
first pass through the clinical trial process.10
Generally, a clinical trial in the United States subject to FDA guidelines
is a four-step phase or process.11 Phase one of a clinical trial consists of
highly controlled tests with a very small number of people, which is aimed
at evaluating safety, dosage, and potential side effects.12 Phase two increases
the number of people in the study, and further assesses safety and

5. See Joseph Brownstein, Most Babies Born Today May Live Past 100, ABC NEWS,
http://abcnews.go.com/Health/WellnessNews/half-todays-babies-expected-live-past-100/story?id
=8724273 (Oct. 1, 2009) (discussing how children born in 2009 will most likely live to be older
than 100).
6. See Jacqueline Howard, Double Arm Transplant Will Allow Veteran ‘To Pursue My
Dreams’, CNN (Oct. 5, 2016 7:44 PM), http://www.cnn.com/2016/10/05/health/double-armtransplant-veteran-john-peck.
7. See Anna Magee, How Close Are We To Curing Cancer?, THE TELEGRAPH (Mar. 21,
2016, 7:00 AM), http://www.telegraph.co.uk/wellbeing/health-advice/how-close-are-we-to-curing
-cancer/; see also Anna Hodgekiss, Are We Nearing A Cure For Cancer? Holy Grail is Closer
Than Ever, Oncologist Claims, DAILY MAIL (May 30, 2016 9:38 AM), http://www.dailymail.
co.uk/health/article-3616249/Are-nearing-cure-cancer-Holy-grail-closer-oncologist-claims.html;
Greg Jones, Why Are Cancer Rates Increasing?, CANCER RESEARCH CTR (Feb. 4, 2015),
http://scienceblog.cancerresearchuk.org/2015/02/04/why-are-cancer-rates-increasing/ (noting that
“more people are beating cancer today than ever before. Survival has doubled in the last 40 years.
And half of people diagnosed will survive their cancer for more than 10 tears, an all-time high.”).
8. See Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) Q&A, CTR. FOR
DISEASE CONTROL & PREVENTION, http://www.cdc.gov/vhf/ebola/strive/qa.html (last updated
Apr. 20, 2016); see also German Center for Infection Research, Ebola Vaccine: Promising Phase
I Trials, SCIENCEDAILY (May 3, 2016), https://www.sciencedaily.com/releases/2016/05/1605031
31401.htm.
9. See Yevgeniy Feyman, Shocking Secrets of FDA Clinical Trials Revealed, FORBES (Jan.
24, 2014), http://www.forbes.com/sites/theapothecary/2014/01/24/shocking-secrets-of-fda-clinical
-trials-revealed/#7d5a08f92279.
10. See Clinical Trials, PHRMA, http://www.phrma.org/advocacy/research-development/
clinical-trials (last visited Mar. 28, 2017) (discussing the process and steps of the clinical trial process).
11. See Step 3: Clinical Research, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ForPat
ients/Approvals/Drugs/ucm405622.htm (last updated Oct. 14, 2016).
12. Id. (noting first step of clinical trial process).
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effectiveness. During phase three, the experimental drug is administered
to large groups of people, and is aimed at confirming effectiveness through
monitoring and trial data collection.14 Lastly, phase four occurs after the
drug is on the market to monitor risks associated with long-term use and the
drug’s effectiveness in various populations.15
According to the FDA, 70% of drugs pass phase one, 33% pass phase
two and 25% to 30% pass phase three.16 To put those numbers into more
understandable terms, according to the FDA, roughly six out of every one
hundred drugs that begin the clinical trial process make it past phase three.
Moreover, some sources suggest that the time from lab to market for a new drug
is about 15 years,17 and costs can be upwards of $30 to $40 million just for the
first three phases of a clinical trial, and then another $30 to $40 million if the
drug makes it to phase four.18 Some studies even suggest that when accounting
for all the “behind the scenes” costs, the average cost of getting a drug from lab
to market could be as high as $1.3 billion.19
These high costs and lengthy processes naturally raise questions — how
can this process be improved? Under the construct of the burdensome
regulations and requirements, how can medicine and the pharmaceutical
industry meet the needs of patients and future generations faster, safer, and
more economically? How can the sponsoring pharmaceutical companies,
contracted research organizations, site investigators, and others reduce the
time it takes a treatment or drug to go from lab to market? One option is to
expand the use of software platforms to reduce cycle times throughout the
clinical trial process.
Commensurate, and even surpassing the profound advancements in
Western medicine in the last century, software, communication, imaging and
related technologies have been exponentially advancing in the last several

13. Id. (noting second step of clinical trial process).
14. Id. (noting third step of clinical trial process).
15. Id. (noting fourth step of clinical trial process).
16. See id. (stating what percentage of drugs pass through each phase).
17. See Clinical Trials 101, CROHNS & COLITIS FOUND. OF AM., http://www.ccfa.org/resou
rces/clinical-trials-101 (last visited Mar. 28, 2017) (noting length of average clinical trial).
18. See Aylin Sertkaya et al., Examination of Clinical Trial Costs and Barriers for Drug
Development, E. RESEARCH GRP. (July 25, 2015), https://aspe.hhs.gov/report/examination-clinic
al-trial-costs-and-barriers-drug-development.
19. See Avik S. A. Roy, Stifling New Cures: The True Cost of Lengthy Clinical Drug Trials,
5 PROJECT FDA REPORT, (March 2012) (discussing the behind the scenes costs associated with
clinical trials, and how those costs can drive the total cost to over $1 billion).
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decades.20 Technological and medical advancements go hand in hand.21
Other industries that are of similar size to healthcare and pharmaceuticals
have evolved their business models to incorporate and accelerate growth and
success using technological advances. For example, in the financial services
industry, virtually all major banks have some form of online banking, and
according to recent research, about 50% of United States adults use online
banking.22 Further, about 35% of cell phone users use their smart phones to
bank online.23 There are even some banks that are exclusively online and
have no physical, brick and mortar branches.24
So, with technology permeating so many facets of other industries, why
has the medical and pharmaceutical industry lagged in matching the pace of
technological advancement? Specifically, what are the legal and policy risks
associated with hastening the clinical trial process by utilizing technology
based clinical trial platforms versus traditional paper-based methods? That
is the question this article seeks to answer.
First, this article will look to the recent legal trends surrounding
technology in healthcare and the pharmaceutical industry generally. Then,
this article will analyze traditional paper intensive approaches to key
elements of clinical trials including; site feasibility, document distribution,
and informed consent and discuss how those areas could be improved by the
use of technology. Potential new liability exposures will be analyzed in light
of the expanded use of technology in the clinical trial process. The policy
section will discuss steps regulatory bodies have taken to embrace
technological advances, and project where technology and medicine are
headed. Finally, this article will conclude with a policy discussion that
compares the benefits of new technologies to possible risk increases and
suggest ways that the laws and regulations can continue to evolve to harness,
expand, and encourage new technologies.

20. See Max Roser, Technological Progress, OUR WORLD IN DATA (2016), https://ourworld
indata.org/technological-progress/ (discussing the exponential growth of technology).
21. See Bianca Banova, The Impact of Technology on Healthcare, AM. INST. OF MED. SCI. &
EDUC. (Mar. 28, 2013), https://www.aimseducation.edu/blog/the-impact-of-technology-on-healthcare.
22. See Susannah Fox, 51% of U.S. Adults Bank Online, PEW RESEARCH CTR. (Aug. 7, 2013),
http://www.pewinternet.org/2013/08/07/51-of-u-s-adults-bank-online; see also Evan Bakker,
Technology is Disrupting the Financial Services Industry – Here’s How, BUS. INSIDER (Feb. 22,
2016), http://www.businessinsider.com/technology-is-changing-the-financial-services-industry2016-1.
23. See id.
24. See ALLY FINANCIAL, https://www.ally.com/about/ (noting that Ally is a completely
online bank); see also Marycela Diaz-Unzalu, Technology Trends Affecting the Banking Industry,
FED. RESERVE BANK OF ATLANTA (Mar. 28, 2014), https://frbatlanta.org/education/publications/
extra-credit/2014/spring/technology-trends-affecting-banking-industry.
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II. Background: The Intersection of Law, Technology, Medicine,
and Business
Since the late 1990s, policy and legislative steps have been taken in the
United States to promote the implementation and adoption of electronic
business practices. In 1999, the National Conference of Commissioners on
Uniform State Laws (NCCUSL) promulgated the Uniform Electronic
Transactions Act (UETA).25 According to the NCCUSL, the goal of the
UETA was to make a “comprehensive effort to prepare state law for the
electronic commerce era.”26 As of 2016, the UETA has been adopted by 47
states,27 and governs “electronic records and electronic signatures relating to
a transaction.”28
One year later, the federal government joined the e-commerce movement
by enacting the Electronic Signatures in Global and National Commerce Act
(hereafter “ESIGN”).29 Effectively, this act assured that electronic signatures
and agreements would be given the same enforceability as paper agreements.30
Although neither the ESIGN Act nor the UETA are directly implicated in the
discussion relevant to this article, they gave electronic agreements and
signatures the same legal force as paper agreements and signatures.31 Without
the backbone of these acts, e-commerce and e-business (and thus, e-clinical
trials) would carry no legal weight at all.32

25. See Electronic Transactions Act Summary, NAT’L CONFERENCE OF COMM’RS ON UNIF.
STATE LAWS, http://www.uniformlaws.org/ActSummary.aspx?title=Electronic%20Transactions
%20Act (last visited Mar. 28, 2017).
26. See id. Although every state that has adopted the UETA has codified it in their own way,
an example of how the UETA was written into law can be seen in FLA. STAT. ANN. § 668.50
(LexisNexis 2016).
27. See Electronic Transactions Act, NAT’L CONFERENCE OF COMM’RS ON UNIF. STATE
LAWS, http://www.uniformlaws.org/Act.aspx?title=Electronic%20Transactions%20Act (last
visited Mar. 28, 2017) (showing map of what states have adopted the UETA).
28. NAT’L CONFERENCE OF COMM’RS ON UNIF. STATE LAWS, supra note 25.
29. See 15 USCS § 7001 (discussing provisions of the ESIGN Act).
30. See 15 USCS § 7001(a)(1) (“a signature, contract, or other record relating to such
transaction may not be denied legal effect, validity, or enforceability solely because it is in
electronic form”). Further, § 7001(a)(2) states “a contract relating to such transaction may not be
denied legal effect, validity, or enforceability solely because an electronic signature or electronic
record was used in its formation.”
31. See id.
32. See Howard Burde, The HITECH Act – An Overview, 13 AMA J. OF ETHICS, (VIRTUAL
MENTOR) no. 3, 2011 at 172–75.
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A. The Dynamic Duo of HIPAA and HITECH
1.

The Health Insurance Portability and Accountability Act

In 1996, congress passed the Health Insurance Portability and
Accountability Act (hereinafter “HIPAA”).33 Although HIPAA affected a
number of areas of the law, it is most known for the impacts it has on patient and
medical record privacy.34 Specifically, Section 264 of the Administrative
Simplification provisions is commonly referred to as the “Privacy Rule.”35 The
main goal of HIPAA and the Privacy Rule specifically is to “define and limit the
circumstances in which an individual’s protected health information may be
used or disclosed by covered entities.”36
HIPAA’s Privacy Rule “[applies] to health plans, health care
clearinghouses, and to any health care provider who transmits health
information in electronic form.”37 The Privacy Rule is focused on
minimizing the release of individually identifiable health information (IIHI)
by any of the abovementioned-covered entities.38 In addition to obvious
examples of IIHI, things like credit card numbers and telephone numbers are
also considered to be sources of IIHI.39 Further, the Privacy Rule enacted a
“minimum necessary” standard for disclosing medical information, which
requires that covered entities make “reasonable efforts to limit protected
health information to the minimum necessary to accomplish the intended
purpose of the use, disclosure, or request.”40 In the early 2000s, the Office
for Civil Rights (the branch of the Department of Health and Human Services
responsible for investigating HIPAA violation claims) was regularly
receiving “over one hundred privacy-related complaints per week.”41
In addition to the privacy components of HIPAA, the law also includes
security measures. The purpose of the security rule is to require “appropriate
administrative, physical and technical safeguards to ensure the

33. See Summary of the HIPAA Privacy Rule, U.S. DEP’T OF HEALTH & HUMAN SERV.,
https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/ (last visited Mar. 28,
2017), (giving an overview of HIPAA).
34. See The HIPAA Privacy Rule, U.S. DEP’T OF HEALTH & HUMAN SERV., https://
www.hhs.gov/hipaa/for-professionals/privacy/ (last visited Mar. 28, 2017).
35. See U.S. DEP’T OF HEALTH & HUMAN SERV., supra note 33.
36. See Elizabeth Hutton & Devin Barry, 2004 Privacy Year In Review Annual Update: Medical:
Privacy Year In Review: Developments in HIPAA, 1 INFO. SOC’Y J.L. & POL’Y 347, 352 (2005).
37. See U.S. DEP’T OF HEALTH & HUMAN SERV., supra note 33 (discussing the HIPAA
privacy rule).
38. See Hutton & Barry, supra note 36, at 352.
39. Id.
40. See 45 C.F.R. § 164.502(b)(1).
41. See Hutton & Barry, supra note 36, at 355.
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confidentiality, integrity, and security of electronic protected health
information.”42 In today’s world, the very real threat of computer hacking
by third parties is a serious consideration for the healthcare industry, being
hacked and the resulting exposure of IIHI would open up a covered entity to
liability under HIPPA.43
2.

The Health Information Technology for Economic and Clinical Health Act

In 2009, HIPAA, and technology in health and medicine took a further
leap into the technology era with the enactment of the Health Information
Technology for Economic and Clinical Health Act (HITECH Act).44 The
HITECH Act was passed as part of the American Recovery and
Reinvestment Act, which was President Obama’s stimulus package aimed at
pulling the country out of a significant and prolonged recession following
the collapse of financial markets due to poor mortgage loan practices and
securitization.45 The goal of the HITECH Act was to implement a national
system of electronic record keeping for medical records.46 The HITECH Act
aimed to accomplish widespread adoption of Electronic Health Record
Systems (EHRs) with the use of incentive payments to health care industry
clinicians and participants.47
Although the HITECH Act is predominantly aimed at the
implementation of EHR systems across the United States, it also facilitates
the enforcement of HIPAA.48 In addition to expanding the definition of who
must comply with HIPAA, the HITECH Act also created a security breach
notification requirement.49 In the event of a breach, the company responsible
for holding the data must notify the affected customers and the government,

42. See The Security Rule, U.S. DEP’T OF HEALTH & HUMAN SERV., http://www.hhs.
gov/hipaa/for-professionals/security/ (last visited Mar. 28, 2017).
43. See Leon Rodriguez, Privacy, Security, and Electronic Health Records, HEALTH IT BUZZ
(Dec. 12, 2011), https://www.healthit.gov/buzz-blog/privacy-and-security-of-ehrs/privacy-security
-electronic-health-records/; see also Kevin McCarthy, HIPAA and Hacking: What You Need to
Know, NUEMD (Apr. 14, 2016), http://www.nuemd.com/news/2016/04/14/hipaa-hacking-youneed-know (noting the increase in hacking attempts aimed at healthcare infrastructure).
44. See Kirk J. Nahra, A New HIPAA Era Emerges, 1005 PLI/PAT 467, 471 (2010) (Westlaw).
45. See About the Recovery Act, WHITE HOUSE, https://www.whitehouse.gov/recovery/
about (last visited April 19, 2017).
46. See Kara J. Johnson, HITECH 101, AM. BAR ASS’N, http://www.americanbar.org/grou
ps/young_lawyers/publications/the_101_201_practice_series/hitech_101.html (last visited Mar.
28, 2017).
47. See id. (positing that the HITECH Act “was passed as a monetary incentive plan for
hospitals to begin converting to electronic records.”).
48. See id. (reasoning that “HITECH significantly changes both enforcement and sanctions
with regard to health care privacy and security requirements under HIPAA.”).
49. See Nahra, supra note 44.
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and if the breach affects more than 500 people, the media must also be
notified.50 By requiring notification to affected parties, the HITECH Act not
only holds record holders more accountable but also aims to increase and
preserve the trust between patients and entities holding their health
information in electronic format.51
Prior to the implementation of HITECH, third-party service providers
were not directly subject to liability for violations of HIPAA; instead they
could be held liable privately to the covered entity utilizing their services
under a breach of contract claim.52 However, pursuant to HITECH,
“business associates are now directly subject to civil and criminal penalties
under HIPAA if they violate . . . security safeguard requirements or the terms
of their business associate agreements.”53 Thus, HITECH increased the
scope of HIPAA by allowing business associates to be held directly liable
for violations of the privacy rule.54
Additionally, HITECH dramatically increased the possibility of
enforcement of HIPAA because it allows a state attorneys general to bring
HIPPA enforcement actions, in addition to ramping up the penalties violators
can face.55 Prior to the HITECH Act, HIPAA violators were subjected to
penalties of $100 per known violation, with a damages cap of $25,000 per
year.56 Considering that the size of the United States healthcare industry
where many large players have revenues in the tens of billions or more,57
with a total market size of upwards of $3 trillion, the $25,000 fine levels may
have been inadequate to act as a deterrent.58 The stakes are higher under the
50. See HITECH Breach Notification Rule, U.S. DEPARTMENT OF HEALTH AND HUMAN
SERVICES, https://www.hhs.gov/hipaa/for-professionals/breach-notification/ (last visited Mar. 28,
2017) (analyzing the breach notification requirement implemented by the HITECH Act).
51. See id.
52. See Norbert F. Kugele, HIPPA Goes HITECH: How the HITECH Amendments to HIPPA
Impact Employer-sponsored Health Plans, 35 MI TAX L. 19, 20 (2009).
53. See id.
54. See id.
55. Health Information Technology for Economic and Clinical Health Act, § 13410,
amending Social Security Act § 1176, codified at 42 U.S.C. § 1320d-5; see also Health Information
Technology for Economic and Clinical Health Act, § 13410(e)(1); see also HIPAA Violations and
Enforcement, AM. MED. ASS’N, http://www.ama-assn.org/ama/pub/physician-resources/solutionsmanaging-your-practice/coding-billing-insurance/hipaahealth-insurance-portability-accountability
-act/hipaa-violations-enforcement.page? (last visited Mar. 28, 2017).
56. See Kugele, supra note 52, at 19-20.
57. See Laura Lorenzetti, The 10 Biggest Health-Care Companies in the Fortune 500,
FORTUNE (June 20, 2015), http://fortune.com/2015/06/20/fortune-500-biggest-healthcare-compan
ies/ (noting several healthcare companies listed in the Fortune 500 with annual revenues between
$50 to $140 billion).
58. See Dan Munro, U.S. Healthcare Hits $3 Trillion, FORBES (Jan. 19, 2012, 11:52 PM),
http://www.forbes.com/sites/danmunro/2012/01/19/u-s-healthcare-hits-3-trillion/#66b0f34c2f67.
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HITECH Act, with penalties for HIPAA violations ranging from $100 per
violation to $50,000 per violation, with an annual cap of $1.5 million in
penalties.59
a.

The Impact of HIPAA and HITECH on the Clinical Trial Ecosystem

Although HIPAA and HITECH are Acts aimed at the implementation,
security, and privacy of EHRs, they both have substantial impacts
throughout the entire healthcare system. Recently, the impact of these laws
has become even more pronounced as the clinical trial process is, albeit
slowly, going digital.60 The shift from paper to digital clinical trials provides
the framework for speeding up the time from lab to market and will also save
companies who sponsor clinical trials large sums of money. Some research
suggests that life science and other pharmaceutical companies could save as
much as 25% of their annual operating expenditures by working with a
clinical IT system.61 Thus, it comes as no surprise to discover that 66% of
the top 50 pharmaceutical companies are currently digitizing certain parts of
their clinical trial process.62
Throughout the clinical trial process, IIHI is exchanged between
companies, clinicians, and patients. As a result, successfully navigating the
clinical trial process requires compliance with a number of federal laws, like
HIPAA and HITECH. Although there are serious financial and humanitarian
incentives to digitizing the clinical trial process, pharmaceutical companies are
hesitant to fully embrace digital clinical trials because of the potential
compliance issues and the possible increase in liability exposure.63

59. See Kugele, supra text accompanying note 52.
60. See eClinical Solutions Market to Surpass $13 Billion by 2024, Dɪɢɪᴛᴀʟ Jᴏᴜʀɴᴀʟ (Oct.
24, 2016), http://www.digitaljournal.com/pr/3115602.
61. See Elly Earls, Ahead In The Cloud – A New home For Clinical Trial Data,
Pʜᴀʀᴍᴀᴄᴇᴜᴛɪᴄᴀʟ-Tᴇᴄʜ. (Jan. 31, 2012), http://www.pharmaceutical-technology.com/features/feat
ureahead-in-the-cloud-a-new-home-for-clinical-trial-data/ (stating “IBM’s research suggests that
many life sciences organizations could save as much as 25% of their annual operating expenditure
on clinical IT systems by using cloud computing).
62. See Glenn Keet & Eric Morrie, Top eClinical Trends in 2016, CLINCAPTURE, ᴇCʟɪɴɪᴄᴀʟ
Tʀᴇɴᴅ (Mar. 9, 2016), http://www.clincapture.com/blog/top-eclinical-trends-in-2016-12-2/. The
statistics from this article are specific to eConsent adoption, not total eClinical trial adoption.
However, eConsent adoption is one of the biggest hurdles many companies need to overcome in
order to entirely digitize their clinical trial process. See also Electronic Consent Management:
Landscape Assessment, Challenges, and Technology, Hᴇᴀʟᴛʜʜɪᴛ.ɢᴏᴠ (Oct. 29, 2014), available at
https://www.healthit.gov/sites/default/files/privacy-security/ecm_finalreport_forrelease62415.pdf.
63. For a discussion pertaining to potentially increased liability by digitizing the clinical trial
process, see infra, notes 86–99, 108–122, and 135–149.
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A Primer on the Terminology and Business of Clinical Trials

As was discussed at length in Section I of this article, clinical trials are
one of the driving forces behind the advancement of medicine.64 Thus, a
number of entities from the medical industry are involved in some form or
another.65 For example, a clinical trial is led by a principal investigator who
is usually a medical doctor.66 Further, the principal investigator is supported
and assisted by a research team, usually consisting of nurses, other doctors,
social workers, and health care professionals.67
Clinical trials are often paid for (or sponsored) by pharmaceutical
companies or university medical centers.68 However, some federal agencies will
fund clinical trials for specific diseases that are widespread. For example,
federal agencies fund a large proportion of cancer related clinical trials.69
When a sponsoring party wants to begin work on a clinical trial, they
can either perform the research and work themselves, or they can recruit a
contract research Organization or CRO.70 A CRO is a company that is
recruited and contracted by the sponsor “to manage and lead the company’s
trials, duties, and functions.”71 A CRO acts as an agent for the sponsor,
providing expertise and experience in the clinical trial process, while the
sponsor does not need to hire permanent staff for the position.72 CRO’s can
fill many roles throughout the clinical trial process, with some CROs
handling a specific part of the clinical trial and others managing the trial from

64. See supra text accompanying notes 16–24.
65. See Learn About Clinical Studies, U.S. NAT’L INST. OF HEALTH, https://clinicaltrials.
gov/ct2/about-studies/learn (last updated Jan. 2017).
66. See Jeff Kingsley, What is a PI?, ACRP, https://www.acrpnet.org/professionaldevelopment/certifications/pi-certification/ (last visited Mar. 28, 2017) (stating that a “[principal
investigator] holds a doctoral-level degree (PhD, PharmD, DNP, DO, MD, DDS or equivalent
degree) and serves as the principal, sub- or co-investigator[.]”)
67. See Responsibilities of the Research Team, OHIO STATE UNIV. CTR FOR CLINICAL &
TRANSLATIONAL SCI., https://ccts.osu.edu/education-and-training-programs/research-education-a
nd-training-programs/clinical-research-coordinator-resources/responsibilities-of-the-research-team/
(last visited Mar. 28, 2017) (noting that “the research coordinator/nurse oversees and coordinates
the daily activities of clinical research studies”).
68. See id.; see also Freemantle, N. and Stockten, D., The Commercialization of Clinical
Research: Who Pays the Piper, Calls the Tune?, OXFORD JOURNALS (Aug. 1, 2004),
http://fampra.oxfordjournals.org/content/21/4/335.full
69. See Who Conducts Clinical Trials and Who Pays for Them?, BREASTCANCER.ORG,
http://www.breastcancer.org/treatment/clinical_trials/conduct_pay (last updated Aug. 10, 2016)
(noting that many cancer related clinical trials are funded by United States Federal Agencies).
70. See Kathlyn Stone, Contract Research Organization, THE BALANCE (May 2, 2016),
https://www.thebalance.com/contract-research-organizations-cro-2663066.
71. See id.
72. See id.
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site selection to FDA approval.
As a result, CROs are becoming
increasingly popular in the clinical trial world, and can be involved at every
stage of the research and development process in a clinical trial.74
3.

What Steps of the Clinical Trial Process Can be Digitized?

As mentioned in the introduction, the clinical trial process is rather
lengthy, consisting of a number of steps over several years.75 Addressing the
impact of digitizing every single step of the clinical trial process is beyond
the scope of this article, which will focus on a discussion of three separate
steps in the process that are digitizable and examine the impact of digitizing
these three specific steps in terms of benefits to patients and the process
generally, and the effect on possible liability exposure. The specific
processes that will be discussed are the site selection process, document
distribution, and informed consent.
a.

Site Selection

When conducting a clinical trial, one of the preliminary steps is finding
an appropriate site to recruit, interact with and monitor patients participating
in the trial. Locating a site consists of finding the right demographics,
patients, clinicians, hospitals, facilities etc. and can be one of the most
arduous aspects of the clinical trials process.76 However, the current model
for site feasibility planning is outdated, and relies on a “crowdsourcing
approach” instead of data and analytics.77
Generally speaking, site feasibility “is a process of evaluating the
possibility of conducting a particular clinical program/trial in a particular
geographic region with the overall objective of optimum project completion

73. See id.
74. See Ed Silverman, Why Contract Research Organizations Are So Hot, Fᴏʀʙᴇs (Oct. 4,
2011), http://www.forbes.com/sites/edsilverman/2011/10/04/why-contract-research-organizations
-are-so-hot/#5da56611694b.
75. See supra text accompanying notes 11–17.
76. See Melissa Fassbender, ‘Paradigm Shift Needed’ in Trial Site Selection Process,
OUTSOURCING-PHARMA (Mar. 31, 2016), http://www.outsourcing-pharma.com/CommercialServices/Paradigm-shift-needed-in-trial-site-selection-process (reasoning that “site selection has
traditionally been performed using manual, and error prone processes, which use historical, siloed
data — ultimately resulting in too many non-enrolling and under-enrolling sites being selected.”)
77. See Ed Miseta, Proper Feasibility Planning is Critical for Clinical Trial Success,
CLINICAL LEADER (June 22, 2015), http://www.clinicalleader.com/doc/proper-feasibility-plan
ning-is-critical-for-clinical-trial-success-0001 (suggesting that data driven site feasibility processes
will lead to better results); see also Kenneth A. Getz, Is Investigative Site Feasibility Feasible?,
APPLIED CLINICAL TRIALS ONLINE (July 1, 2008), http://www.appliedclinicaltrialsonline.
com/investigative-site-feasibility-feasible (noting that “[s]ponsors, CROs and investigative sites
widely agree that site feasibility assessments are frequently exercises in futility.”)
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in terms of timelines, targets, and costs.”78 This is usually accomplished by
sending out feasibility surveys to potential sites, which ask about
demographics and enrollment prospects.79 However, the surveying method
can be problematic, because surveys are subject to over and under
estimations.80 Further, it is not unheard of for potential sites to be
purposefully overconfident in their enrollment projections in order to win the
study grant and become a host site for the trial.81
Therefore, the current process of finding an adequate site to host a
clinical trial is in many respects left up to chance.82 Depending on the
complexity of the drug and associated illness that is the subject of a
prospective clinical trial, finding an adequate site may be very difficult. As
an extreme example, any sort of large-scale research pertaining to the Ebola
outbreak would necessarily have to occur in West Africa, as that is where the
outbreak of the disease has occurred.83 Locating a site that has the
technological capabilities to host a clinical trial in West Africa could
presumably prove difficult.
Further, even if a site is found, and patients are recruited, it is reported
that “less than half of studies completed enrollment within the planned
timeline.”84 Patient recruitment and retention has always been one of the
biggest hurdles that sponsors and CROs need to overcome.85 Thus, sponsors
and CROs can be forced to restart the site evaluation process, with less time
and money than was available at the commencement of the trial. Regardless
of the problems that a sponsor could encounter while seeking a site for a

78. See Viraj Rajadhyaksha, Conducting Feasibilities in Clinical Trials: An Investment to
Ensure a Good Study, NAT’L CTR FOR BIOLOGY INFO. (July-Sept. 2010), https://www.ncbi.nlm.
nih.gov/pmc/articles/PMC3146075/ (discussing the importance of a properly performed site
feasibility process).
79. See Miseta, supra note 77.
80. See Getz, supra note 77.
81. See id.
82. See Miseta, supra note 77 (noting that “there would also be questions around how the
sites produced their answers, and whether there was any scientific evidence to back it up.”)
83. See 2014 – 2016 Ebola Outbreak in West Africa, CTR FOR DISEASE CONTROL,
https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/ (last updated June 22, 2016) (reasoning
that “since march 2014, West Africa has experienced the largest outbreak of Ebola in history”).
84. See Kenneth A. Getz, Enrollment Performance: Weighing the “Facts”, APPLIED
CLINICAL TRIALS, (May 1, 2012), http://www.appliedclinicaltrialsonline.com/enrollment-perform
ance-weighing-facts?id=&sk=&date=&pageID=2; see also Interview by Elisabeth Fischer
interviewing Marta Rayo Lunar, Trial and Error: Site Selection for Clinical Studies,
PHARMACEUTICAL-TECH., http://www.pharmaceutical-technology.com/features/feature130340/.
85. See Olivia Diamond, Overcoming Patient Recruitment and Retention Hurdles, MEDRIO
(Nov. 23, 2015), http://medrio.com/partners/overcoming-patient-recruitment-and-retention-hurdles/
(reasoning that “Phase I through Phase III trials are, on average, 30% longer than planned due to
patient recruitment issues and low patient retention”).
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clinical trial, the current process is undoubtedly a driving force in the
exploding time and cost associated with drug development.
i.

Site Selection and the Impact of Technology

Utilizing a digital site selection program could likely save a huge
amount of time and money. The utilization of a digital database for site
selection is well within the limits of technology and the law and is already
being used in the industry.86 Specifically, a central database can store
information gathered from prior trials and site-reported experience and
competencies. This data can include information about investigators,
patients, disease, or conditions and the success rates of sites that hosted trials
in the past. With this wealth of information, computer generated algorithms
compute and predict which sites would most likely have the optimum results
for a specific clinical trial.87
This process would save time and money for both the sponsor and the
site. Traditionally, every time a site is considered to host a clinical trial, the
site must fill out and complete a feasibility survey.88 However, in a digital
process, a survey would only need to be completed one time, and the answers
could be stored in a database. Even Better, potential sites could have access
to an online application or profile that they can continually update as the
site’s specific information changes.89
Utilizing a digital process for site feasibility reduces not only time, but
also costs associated with printing and mailing surveys required for site
selection. Employing a traditional, paper based method, the CRO would
send potential sites a survey, wait several days for the site to send it back,
and then transform the answers into useful data.90 However, if a digital
process was utilized, potential sites could answer a survey one time, and then
an algorithm would compute the data and suggest the sites that are most
likely to be successful for each specific clinical trial.91

86. See Craig Morgan, It’s Site Selection, Not a Toss of the Dice, CLINICAL INFORMATICS
NEWS (June 28, 2016), http://www.clinicalinformaticsnews.com/2016/6/27/its-site-selection-nottoss-dice.aspx.
87. See id.
88. See Ed Miseta, Bring Down The Cost Of Clinical Trials With Improved Site Selection,
CLINICAL LEADER (Dec. 19, 2013), http://www.clinicalleader.com/doc/bring-down-the-cost-ofclinical-trials-with-improved-site-selection-0001.
89. See id.
90. See Morgan, supra note 86.
91. See Miseta, supra note 88.
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A digital site selection process would result in more accurate data.92 If
a site is asked to fill out a selection survey once, without the potential reward
of a specific clinical trial, the site is more likely to be candid in their
responses.93 An approach like this could dissuade a site from responding to
selection surveys with an eye toward participating in a specific clinical trial,
because inflating numbers in the hopes of getting one trial may be
detrimental to getting a better trial in the future.94 By utilizing a fully
technology based method of site selection, potential sites would only respond
to one survey, and would be unable to tailor their responses to a specific
clinical trial.95 Thus, responses could be more reliable, and thus provide
sponsors and CROs with more accurate data, which would hopefully
minimize the inclusion of sites that under recruit or are not successful in
recruiting any participants.96
Further, neither HIPAA nor HITECH would act as a barrier to the industry
adopting a digital site selection process. The data needed to create a site
selection database would not implicate individually identifiable health
information; only specific data points are required. Thus, because the data
would not be tied to specific people, and all identifying information could be
stripped away, HIPAA’s privacy rule would not be implicated.97
The logical endpoint of this approach could be a ranking of different
sites based on patient recruitment outcomes and success in past clinical trials.
However, ranking of sites would necessarily be based only on past
performances, and thus would only include the specific trials that the sites
had previously hosted. Accordingly, some site representatives agree that this
technology would be beneficial to sites too, because it can help determine
“which data should be viewed as reliable in predicting future behavior,

92. See Morgan, supra note 86 (noting that electronic site selection methods can provide
sponsors “with intelligence based on data documenting sites’ past performance, size of patient
database, staff expertise in certain therapeutic areas, and ability to produce quality data and manage
a clinical trial”).
93. See Miseta, supra note 88.
94. See id.
95. See Miseta, supra note 88.
96. For a discussion of problems with the current survey method of identifying sites for
clinical trials, see supra notes 76-85. For a discussion specific to fabrication of survey answers and
how technology can improve the process of site selection, see Sameer Tandon, The State of
Feasibility Assessments and Strategies to Improve Your Methodology, PHARM. OUTSOURCING
(Jan. 29, 2014), http://www.clinicaltrialsarena.com/news/operations/the-state-of-feasibility-assess
ments-and-strategies-to-improve-your-methodology-4986833 (noting that “[s]ites frequently tell
sponsors what they want to hear and this is often in response to the types of questions being asked.”).
97. For a discussion of HIPAA’s privacy rule, and how it is implicated by Individually
Identifiable Health Information (IIHI), see supra text accompanying notes 37–41.
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versus which merely reflects the specifics of a particular study.”98
Accordingly, a site selection database that is established with collaboration
by the sites would include only accurate data, and thus would be beneficial
to both sponsors and sites.99
b.

Document Distribution

Due to the large number of people and entities working together on a
clinical trial, communication and information sharing is a critical part of a
successful clinical trial. For example, the efficacy of the trial relies on proper
distribution of trial related — clinical information.100 Further, credentials and
training materials must be shared among the healthcare professionals and
pharmaceutical entities taking part in the trial.101
In small scale, localized, clinical trials, document distribution is not
impossibly daunting — most paperwork can be exchanged via trackable
delivery methods such as certified mail. However, increasingly in the modern
era numerous clinical trials are big, multisite, global projects.102 These large,
multi-site trials are placing new strains on the paper based document distribution
framework that some industry participants continue to use.103 Further, this
problem is unlikely to go away, as clinical trials are steadily growing in size,
geographic disbursement, and therefore complexity.104

98.
99.
100.

See Morgan, supra note 86.
See id.
See Vito Anthony Losito, Manage Trial Master Files via Investigative Portals, APPLIED
CLINICAL TRIALS ONLINE (Feb. 1, 2011), http://www.appliedclinicaltrialsonline.com/managetrial-master-files-investigative-portals.
101. See Nick Paul Taylor, Digital Documents: Can Electronic Tools Ease Biopharma’s
Clinical Trial File Headaches?, FIERCE BIOTECH (Jan. 27, 2014 6:57 AM), http://www.
fiercebiotech.com/r-d/digital-documents-can-electronic-tools-ease-biopharma-s-clinical-trial-file
headaches (noting that “sponsors have formed deep collaborations with service providers” and that
“sharing paper documents in an outsourced system is a headache for sponsors, and the problem is
magnified by the globalization of late-phase trials”).
102. See Global Clinical Research Market to Reach $60 Billion in 2020, CLINCAPTURE (Nov.
2, 2015), http://www.clincapture.com/blog/global-clinical-research-market-to-reach-60-billion-in2020/ (discussing the expected growth of global clinical trials).
103. See Wenle Zhao et al., An Electronic Regulatory Document Management System for a
Clinical Trial Network, NAT’L CTR FOR BIOTECHNOLOGY INFO. (Jan. 1, 2011), https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC2829838/ (reasoning that global clinical trials create new
challenges for document distribution including “the large number of documents to be collected and
maintained, the complexity associated with simultaneous multiple project operations, [and] the
need for document file sharing by multiple owners”).
104. See Taylor, supra note 101; see also Global Trends in Clinical Trial Logistics: 2020
Perspective, COREX, http://corex-depot.com/expertise/white-papers/global-trends-in-clinicaltrial-logistics-2020-perspective/ (last visited Mar. 15, 2017) (discussing the growth of clinical trials
on a global scale).
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Throughout the clinical trial process, the most important documents and
information available to parties in the trial is commonly referred to as the
Trial Master File (“TMF”).105 The distribution of the TMF is crucial to the
safety of participants, along with gathering and maintaining critical FDA
reportable data throughout the process. Although TMF distribution seems
to be a perfect candidate for a transition to electronic distribution, many of
the industry leaders in the pharmaceutical arena are hesitant to vacate ink
signature forms.106 However, due to the expected growth of clinical trials,
and the trend towards utilizing sites around the world, the traditional paper
method of TMF distribution will need to make serious advances in
methodology and logistics, or be replaced altogether.107
i.

Document Distribution and the Impact of Technology

The process of document distribution is in serious need of a digital
overhaul. Digitizing the document distribution process would save both time
and money, and would likely open communication channels between all the
parties working on a clinical trial. Instead of sending documents in the mail,
instant access is possible in at least two separate ways.
First, the TMF and other important documents can be securely stored
on a specific server, which could be accessed remotely.108 By doing
document distribution by remote access, companies minimize the risk of the
documents being improperly stored by third parties, lost in transit, or
intercepted during transport.109 Frankly, document distribution would be
considered an antiquated term, because the documents are not actually being

105. See Losito, supra note 100.
106. See Cutting Edge Information, By 2020, Global Distribution of Electronic TMF
Documents is Projected to Increase 63% Over 2015, MARKET WIRED (June 8, 2016),
http://www.marketwired.com/press-release/by-2020-global-distribution-electronic-tmf-document
s-is-projected-increase-63-over-2015-2132475.htm (discussing that some companies “believed
signatures shouldn’t be done electronically for their TMF”).
107. See Sheila Mahoney and Toni Lakin, Moving From Paper to Electronic TMFs,
CONTRACT PHARMA (Oct. 9, 2013), http://www.contractpharma.com/issues/1013/view_features/
moving-from-paper-to-electronic-tmfs (noting that when Paper TMFs are “locked away in a file room,
other team members need to travel to access it or make special requests for copies to be made”).
108. For an overview and additional background information about remote server access, see
A Beginner’s Guide to Remote Access Software, REMOTE ACCESS, http://www.remoteaccess.org/
(last visited Mar. 15, 2017) (positing that “[c]omputing power and network bandwidth have made
accessing and sharing data between a variety of different machines across vast distances not only
easier but also more secure”).
109. See Kevin Jackson, The Top 5 Benefits of Remote Network Monitoring, HELPSYSTEMS
(Dec. 14, 2016) https://www.helpsystems.com/resources/articles/top-5-benefits-remote-networkmonitoring (noting the security benefits of remote access technology when end to end encryption
is utilized).

202

HASTINGS SCIENCE AND TECHNOLOGY LAW JOURNAL

[Vol. 9:2

110

distributed, the login credentials are. Instead of sending out copies of the
TMF and other documents, one copy of the documents would be saved to a
secure server. Then, the company holding the TMF could manage and
circulate login credentials. That way, only one copy of the TMF actually
exists, but that one copy can be viewed by multiple people simultaneously
from around the world.111
Further, the pharmaceutical industry’s reluctance to adopt electronic
signatures is shortsighted.112 Within the TMF, various forms and releases
need to be signed by patients and doctors.113 Since the passage of the ESIGN
Act in 2000, electronic signatures hold the same merit as their ink
counterparts.114 Additionally, the ESIGN Act bars state law from preempting
the validity of electronic signatures.115 Although a state may enact their own
law in place of the ESIGN Act, the state statute must “[specify] the alternative
procedures or requirements for the use or acceptance (or both) of electronic
records or electronic signatures to establish the legal effect, validity, or
enforceability of contracts or other records.”116
Beyond the ambit of the ESIGN Act, electronic signatures are also
federally regulated.117 These regulations set out separate validation
requirements for closed network and open network systems.118 Essentially,
the regulations outline higher standards and requirements of authentication
110. See id.
111. See Jennifer Goldsmith, Shredding Paper, Saving Cash: Going Digital with a CloudBased eTMF, CLINICAL INFORMATICS NEWS (Oct. 30, 2014), http://www.clinicalinformaticsnews
.com/2014/10/30/shredding-paper-saving-cash-going-digital-cloud-based-etmf.html
(reasoning
“cloud-based eTMFs are easily and securely accessible by all parties”) (The author also notes that
an additional benefit of cloud-based TMF systems is that it allows the sponsor to continually update
the TMF and review the TMF to make sure that it stays in compliance with federal and state laws.).
Id.
112. See supra text accompanying notes 100-106. For references to the pharmaceutical industries
reluctance to adopt electronic signatures for TMFs, see supra text accompanying note 106.
113. See Losito, supra note 100. (stating that “a TMF consists of thousands of pages, and
includes everything from regulatory documents, correspondence, and data to documentation that
supports compliance with local regulations”).
114. See 15 U.S.C. § 7001(a)(1) (2000) (stating that “a signature, contract, or other record
relating to such transaction may not be denied legal effect, validity, or enforceability solely because
it is in electronic form”).
115. See 15 USCS § 7002 (2000).
116. See 15 USCS § 7002 (a)(2) (2000).
117. See 21 C.F.R. § 11.100 (2017).
118. See 21 C.F.R. § 11.10 (2017) for a list of the controls utilized for closed network systems;
see also 21 C.F.R §11.30 (2017) for a list of the controls utilized for open network systems. The
only difference between the two lists of controls is that the open network systems require all of the
protections of the closed system plus “additional measures such as document encryption and use of
appropriate digital signature standards to ensure, as necessary under the circumstances, record
authenticity, integrity, and confidentiality.
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and security for any electronic signatures relating to the Food and Drug
Administration and the Department of Health and Human Services.119
However, the regulations clearly state that “persons may use electronic
records in lieu of paper records or electronic signatures in lieu of traditional
signatures” so long as the requirements of the regulations are met.120 Thus,
electronic signatures and records are accepted as valid by multiple sources
of authority from the federal government, and there is no requirement for
pharmaceutical companies to continue to utilize paper-based methods.
Another valid concern with electronic document distribution and
storage is the possibility of being the victim of a cyber-attack, or what is
more colloquially referred to as hacking. According to the Department of
Health and Human Services, since 2010, there have been 240 HIPAA
violations resulting from hacking that have affected 500 or more people.121
Although that seems like a high number, when compared to the 764
incidences of paper, laptop, and desktop computer theft resulting in HIPAA
violations during the same time frame,122 the risk of being hacked is lower.
Additionally, by using proper security software, encryption and protocols,
the risk of being hacked can be substantially reduced. Most sophisticated
businesses employ appropriate avoidance tactics such as continually
updating passwords, utilizing malware-scanning software, and keeping
software up to date which drastically minimizes the risk of being hacked.123
So long as affirmative steps are taken to minimize the threat of cyber-attacks,
electronic document distribution is an excellent way to minimize costs and
save time throughout the clinical trial process.
c.

Informed Consent

The most important part of the clinical trial process from a subject
protection and ethical viewpoint is obtaining informed consent from the
individuals who are participating in the clinical trial. Since the horrors of
medical experiments during the Nazi era, and the subsequent adoption of the
Nuremburg Code, informed consent has been the touchstone of ethical
research.124 However, acquiring consent is much more involved than getting

119. See 21 C.F.R § 11.1 (2016).
120. See 21 C.F.R § 11.2 (2016).
121. See Breaches Affecting 500 or More Individuals, U.S. DEP’T OF HEALTH & HUMAN
SERV. OFFICE OF CIVIL RIGHTS, https://ocrportal.hhs.gov/ocr/breach/breach_report.jsf;jsessionid
=8E03A0B57574BDB35FF1AEFE5DE51A95 (last visited Mar. 29, 2017).
122. See id.
123. See Jason Karn, The Top 10 HIPAA Violations and How to Prevent Them, NUEMD (June
16, 2015), http://www.nuemd.com/blog/top-10-hipaa-violations-prevent-them.
124. See History of Research Ethics, UNIV. OF MISSOURI-KANSAS CITY, http://ors.umkc.edu
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a signature on a consent form. Obtaining informed consent requires “full
disclosure of the nature of the research and the participant’s involvement;
adequate comprehension on the part of the potential participant; and the
participants voluntary choice to participate.”126 Accordingly, obtaining
informed consent should be viewed as a bi-directional and ongoing
communication process, not a one-time meeting and one-way disclosure
resulting in a signed piece of paper.127
Prospective participants of a clinical trial must be fully informed about
the potential risks and rewards of participating in the clinical trial, and be
given “sufficient opportunity to consider whether or not to participate” in the
study.128 Unfortunately, explaining the intricacies of a clinical trial may
become exponentially more difficult as medicine continues to advance. For
example, even the best of clinicians could have a hard time explaining to a
patient with no medical background or knowledge how a new, cutting edge
medicine is interacting with the body.129
Additionally, participants in the clinical trial process must be given the
opportunity to ask questions about the treatment, and should be encouraged
to seek clarification if they do not comprehend something relevant to the
clinical trial.130 Unfortunately, providing participants with the opportunity
to ask questions can be stifled by two factors. First, some patients may not
know what to ask; depending on the complexity of the treatment; individuals
may lack the requisite comprehension of the material to ask relevant
questions. Second, individuals may be too intimidated or embarrassed to ask

/research-compliance-(iacuc-ibc-irb-rsc)/institutional-review-board-(irb)/history-of-research-ethics
(last visited Mar. 29, 2017).
125. See 21 C.F.R. § 50.20 (2017) (listing the requirements for informed consent); see also
Informed Consent for Clinical Trials, http://www.fda.gov/ForPatients/ClinicalTrials/Informed
Consent/default.htm (last visited Mar. 26, 2017).
126. See Required Components of Informed Consent, CORNELL UNIV., https://www.irb.corn
ell.edu/forms/consent.htm (last visited Mar. 29, 2017) (analyzing the requirements for fully
informed consent); see also 21 C.F.R. § 50.25 (2011) (discussing the elements of informed consent
specific to clinical trials).
127. See Helen L. Stiffler, Guidelines for Obtaining Informed Consent for Clinical Research,
APPLIED CLINICAL TRIALS ONLINE (Nov. 2, 2003), http://www.appliedclinicaltrialsonline.com/
guidelines-obtaining-informed-consent-clinical-research.
128. See 21 C.F.R. § 50.20 (2017).
129. See Jennifer Fong Ha and Nancy Longnecker, Doctor-Patient Communication: A Review,
10 OCHSNER J., 38 (Spring 2010), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184
/#i1524-5012-10-1-38-DiMatteo1 (finding that “75% of orthopedic surgeons surveyed believed
that they communicated satisfactorily with their patients, but only 21% of the patients reported
satisfactory communication with their doctors. Patient surveys have consistently shown that they
want better communication with their doctors”).
130. See Informed consent for clinical Trials, U.S. FOOD & DRUG ADMIN., http://www.fda.
gov/ForPatients/ClinicalTrials/InformedConsent/default.htm (last updated Feb. 25, 2016).
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the research team a question.131 While these barriers to informed consent seem
like speculation, some studies suggest that nearly one out of every five
prospective participants in a clinical trial had difficulty understanding the
informed consent document, and “15% were not satisfied that their question has
been answered during the consent process.”132
As discussed above in connection with trial related document
distribution — large scale, global clinical trials are increasing in number.133
As participants and doctors begin clinical trials that cross the globe,
increased confusion and lack of comprehension is likely to proliferate
commensurate with an international focus which will also bring mounting
language barriers.134
Although informed consent seems like a minor part of the clinical trial
process, it is undeniably a critical aspect of ethical trials and patient care.
Unlike a traditional doctor patient relationship, the research team in a clinical
trial has a primary goal of scientific and medical advancement, which can be
at odds with the best interests of the patient.135 Thus, for the sake of patient
protection, fully informed consent and comprehension of the clinical trial is
paramount.
i.

Informed Consent and the Impact of Technology

As mentioned previously in this article, some pharmaceutical industry
leaders have already begun to adopt electronic informed consent, or
“eConsent” systems.136 Additionally, in March 2015, the FDA issued draft
guidance on the use of electronic informed consent systems, which the FDA
defined as “[using] electronic systems and processes that may employ
multiple electronic media . . . to convey information related to the study and

131. See Are You Too Embarrassed to Ask Your Doctor?, WEBMD (May 9, 2005),
http://www.webmd.com/fitness-exercise/features/are-you-too-embarrassed-to-ask-your-doctor#1
(noting that fear of asking a doctor an embarrassing question is a common phenomenon).
132. See Beverly H. Lorell et al., Informed Consent in Clinical Research: Consensus
Recommendations for Reform Identified by an Expert Interview Panel, SAGEPUB (July 15, 2015),
http://ctj.sagepub.com/content/12/6/692.full.pdf+html.
133. See supra, text accompanying note note 102.
134. See Lokesh P. Nijhawan et al., Informed Consent: Issues and Challenges, 4 J. ADV.
PHARM. TECH. RES. 134 (2013), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777303/ (citing
language barriers as a challenge in obtaining informed consent).
135. See Benjamin Mason Meier, International Protection of Persons Undergoing Medical
Experimentation: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 516
(2002) (noting that “informed consent levels the playing field, providing the subject with the tools
necessary to make a decision contrary to the wishes of the physician.”).
136. See Keet and Morrie, supra text accompanying note 62.
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to obtain and document informed consent.” Although nothing in the draft
guidance is legally binding authority, it sheds light on where the FDA
unofficially stands in regards to eConsent adoption.138 In fact, the FDA’s
draft guidance on the issue suggests that the FDA supports and will permit
the use of electronic media in the informed consent process.139
Throughout the draft guidance, and in the federal regulations governing
consent, the FDA stresses the importance that patients understand the
information that is being conveyed to them.140 This is where the industry
can harness the positive potential of eConsent. Instead of a piece of paper
with writing on it, a complete eConsent package could be a downloadable
file that a potential patient can review at their own pace in the comfort of
their home or with their clinician, at the office or via video or telephone.141
Instead of black and white text, the eConsent platform could include videos
and interactive charts to keep the patient interested in the material.142
Additionally, hyperlinks could be utilized to give simple definitions for
complicated medical terminology.143
Further, it is fully within the realm of technological possibility for realtime chatting to occur between a patient and a medical professional. Subjects
could even submit questions anonymously to a centralized database, where
they would be stored until an in-person meeting between a group of patients
and medical professionals. Doing so could help alleviate anxiety that may
come with asking a question in person, and could even help address a
common dilemma; patients not knowing what to ask - because of the belief
that another patient will ask a question for them.
For confirmation of patient consent review, there is currently
technology in development that tracks the eyes of individuals as they read

137. See Use of Electronic Informed Consent in Clinical Investigations, U.S. FOOD & DRUG
ADMIN. (Dec. 2016), avaialable at http://www.fda.gov/downloads/drugs/guidancecomplianceregu
latoryinformation/guidances/ucm436811.pdf.
138. See id. at 5.
139. See id.; see also Alexander Gaffney, FDA Says it’s OK With Modernizing the Clinical
Trial Informed Consent Process, REGULATORY AFFAIRS PROF’L SOC’Y (Mar. 9, 2015),
http://www.raps.org/Regulatory-Focus/News/2015/03/09/21673/FDA-Says-its-OK-With-Modern
izing-the-Clinical-Trial-Informed-Consent-Process/.
140. See U.S. FOOD & DRUG ADMIN., supra note 137.
141. See Keet & Morrie, supra note 62 (noting the use of text, video, audio, podcasts and
interactive web sites disseminate information about the study to patients).
142. See The Definitive eConsent Solution, DRUGDEV, https://www.drugdev.com/solutions/
drugdev-econsent/ (last visited Mar. 29, 2017) (noting the use of “explanatory videos, audio
narration, and glossary terms to put ‘informed’ back into informed patient consent”).
143. See id.
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on a tablet or computer screen.144 Some eye tracking technology “is capable
of monitoring your eyes in order to define words if you stare at them puzzled,
eliminating non-essential information when you’re skimming” and can even
remind the reader of exactly where he or she previously stopped reading.145
This showcases how eConsent systems can continue to utilize technological
advances for the benefit of patients.
Similarly, eConsent management systems can be used to limit the
possibility of accidently sharing a patient’s health records with a party that
the patient did not consent to viewing the records.146 Through the use of
“structured data”, or data that a computer can understand and extract discrete
elements of, eConsent management systems can control what sections of a
patient’s health records may be disseminated to specific parties.147 For example,
the eConsent system can bar one clinician from seeing drug abuse history of a
patient, but could allow another clinician to see it if the patient consents.148
Accordingly, this type of eConsent management system can “ensure[] the sender
and receiver are authorized to engage in the exchange” while enforcing
applicable federal, state, and local law.149

III. Policy
Since President Obama’s passage of the American Recovery and
Reinvestment Act (ARRA), the digitization of medicine has been on the
forefront of the changing legal landscape.150 Although the ARRA was
limited to the adoption of electronic health records in medicine, it set up the
framework for technology to play a larger part in all stages of medicine,
including clinical trials.

144. See This is Eye Tracking, TOBII, http://www.tobii.com/group/about/this-is-eye-tracking/
(last visited Mar. 29, 2017).
145. See Eliot Van Buskirk, Eye-Tracking Tablets and The Promise of Text 2.0, WIRED (Mar. 25,
2010), https://www.wired.com/2010/03/eye-tracking-tablets-and-the-promise-of-text-20/.
146. See Electronic Consent Management: Landscape Assessment, Challenges, and
Technology, MITRE (Oct. 29, 2014), available at https://www.healthit.gov/sites/default/files/priv
acysecurity/ecm_finalreport_forrelease62415.pdf.
147. See id. at 6.
148. See id.
149. See id. at 6 (reasoning that an eConsent system can “negotiate the entire transaction in an
automated way that enforces the patient’s electronic consent directive”).
150. See American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123 Stat. 115
(2009); see also Sharona Hoffman & Andy Podgurski, 24 BERKELEY TECH. L.J. 1523, 1525 (2009)
(listing one of the goals of the ARRA as “spurring technological advances in science and health.”).
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In September 2013, the FDA released draft guidance regarding the use
of “electronic source data in FDA-regulated clinical investigations.”151 This
shows that the FDA is ready and willing to move the clinical trial process
into the digital age. Although 21 CFR 11 is dedicated to controls for
electronic records and electronic signatures, the references to closed and
open systems show how dated these regulations are.152 Accordingly,
although regulatory bodies have been willing to adopt electronic
advancements in clinical trials, there is still work to be done.
However, this does not mean that the FDA is fighting an electronic
revolution in medicine. To the contrary, they seem to be doing their best to
embrace it. In 2012, the Food and Drug Administration Safety and
Innovation Act (FDASIA) suggested that future FDA submissions for New
Drug Applications should only be accepted in electronic format.153 The
FDASIA stated that this change should take place “no earlier than 24 months
after the issuance of a final guidance issued” relating to the process for
electronic submissions.154 This final guidance was published on May 5,
2015,155 meaning that after May 5, 2017, most drug submissions will need to
be submitted to the FDA via electronic submission.156 Thus, if the
submissions need to be in electronic format, that suggests that the data and
analytics of the associated clinical trials will be too.
Further, in June 2015, the FDA published a notice in the Federal
Register, seeking “demonstration projects to test the capability and evaluate
performance of using an end-to-end Electronic Health Record (EHR)-toElectronic Data Capture (EDC) single-point data capture approach, using
established data and implementation standards in a regulated clinical
151. See Guidance for Industry Electronic Source Data in Clinical Investigations, U.S. FOOD
& DRUG ADMIN. (Sept. 2013), available at http://www.fda.gov/downloads/drugs/guidance
complianceregulatoryinformation/guidances/ucm328691.pdf.
152. See 21 C.F.R. § 11.10, 11.30 (2017) (even the FDA has admitted that the references to
closed and open systems showcase how dated their regulations are). See Leonard Sacks, Electronic
Technology in Clinical Trials, U.S. FOOD & DRUG ADMIN. http://www.fda.gov/downloads/Drugs/
NewsEvents/UCM441299.pdf (last visited Mar. 29, 2017) (noting that the regulations “described
an outdated model of open and closed electronic systems”).
153. See Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, §
1136, 126 Stat. 993 (2012).
154. See id.
155. See Providing Regulatory Submissions in electronic Format – Certain Human
Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications,
U.S. FOOD & DRUG ADMIN. (May 2015), available at http://www.fda.gov/downloads/Drugs/Guid
anceComplianceRegulatoryInformation/Guidances/UCM333969.pdf.
156. See Alexander Gaffney, FDA to Require Electronic Submission of New Drug, Biologic
Files in Next Two Years, REGULATORY AFFAIRS PROF’L SOC’Y (May 7, 2015), http://www.raps
.org/Regulatory-Focus/News/2015/05/07/22116/FDA-to-Require-Electronic-Submission-of-NewDrug-Biologic-Files-in-Next-Two-Years/.
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research environment.”157 In response to this notice, the FDA received 41
proposals from interested parties, seeking to “test standards-based
technology solutions for collection of related healthcare and clinical research
information.”158 This shows two important developments in the growth of
technology and healthcare. First, the FDA is interested in embracing the
digital clinical trial process and they want to do so with the guidance of the
industry.159 Second, industry leaders are ready and willing to assist the FDA
in establishing workable standards for adopting electronic processes in the
clinical trial field.
Moreover, the technological advancements available to facilitate the
drug development process are beneficial to all parties involved. As discussed
at length above, increasing the use of technology saves time and money for
the sponsors and CROs during the developmental stage.160 Additionally,
technology can help the FDA and other regulatory bodies speed up their
approval process, by consolidating data into more manageable electronic
formats.161 But most importantly, technological advances in clinical trials
have the potential to impact patients by speeding up the time it takes new
drugs to go from lab to market.162 The FDA already has guidelines for
expediting the approval of new drugs for serious or life threatening
diseases.163 But the hope for the future is that this “fast-track” would be
unnecessary, because technology would allow all drugs to make it through
the clinical trial process faster and safer.164

157. See Source Data Capture From Electronic Health Records: Using Standardized Clinical
Research Data, 80 Fed. Reg. 36820, 36821(June 26, 2015), available at https://www.gpo.gov/fds
ys/pkg/FR-2015-06-26/pdf/2015-15644.pdf.
158. See Source Data Capture from Electronic Health Records (EHRs), U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequiremen
ts/ElectronicSubmissions/ucm464653.htm (last updated Dec. 18, 2015).
159. See Top eClinical Trends of 2015, SASCOMMUNITY.ORG (2015), http://www.sascommunity.
org/planet/blog/category/fda/ (noting that the FDA is “embracing technology and opening up a dialogue
with experts on how to best channel this revolution in order to advance clinical research.”).
160. See supra text accompanying notes 76–149.
161. See Ed Miseta, The Future of Data and Technology In Clinical Trials, CLINICAL LEADER
(Mar. 22, 2016), http://www.clinicalleader.com/doc/the-future-of-data-and-technology-in-clinicaltrials-0001 (noting the importance of technology changing how data is managed).
162. See infra text accompanying notes 163–164.
163. See 21 U.S.C. § 356 (2016) (stating the process for “expedited approval of drugs for
serious or life-threatening diseases or conditions”).
164. See Danielle Dupont, The Future of Clinical Research: Developing New Drugs Faster
Using Electronic Health Records, ATLAS OF SCIENCE (Jan. 12, 2016), https://atlasofscience.org/
the-future-of-clinical-research-developing-new-drugs-faster-using-electronic-health-records/
(suggesting that the use of Electronic Health Records could speed up clinical trials in the future);
see also Bill Gwinn, Understanding Feasibility For Faster Clinical Trials, CENTERWATCH (Jan.
1, 2016), http://www.centerwatch.com/news-online/2016/01/01/understanding-feasibility-faster-
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There is no doubt that technology is changing the healthcare industry.165
The governing bodies charged with overseeing medicine and healthcare
seem to be embracing the change, albeit rather slowly. However, slow
change is better than no change, and as technological advancements continue
to change the way humans address healthcare, those same changes can be
adopted to speed up the process of clinical trials and drug development.
Although there may be instances where parties risk exposure to greater
liability by embracing technology — that is a risk that the industry as a whole
should accept. The end goal of pharmaceuticals is to produce new treatments
and cures for diseases, and any perceived, slight increased risk, if any, for
achieving that end should not be a bar to the accelerated adoption of
technology.

clinical-trials/ (noting that technological advances in site feasibility selection can speed up the time
of clinical trials).
165. See 3 Ways Technology Has Changed Healthcare, UNIV. OF ILL. AT CHI., http://health
informatics.uic.edu/resources/articles/3-ways-technology-has-changed-healthcare/ (last visited
Mar. 29, 2017).

